Dr. Govindan on the Future of EGFR-Mutant NSCLC

Ramaswamy Govindan, MD
Published: Thursday, May 11, 2017



Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Clinical practice is already changing, Govindan says, as physicians are biopsying patients at the time of disease progression and obtaining cell-free DNA analyses. Moreover, second-line therapy is being decided based on gene alterations.

Secondly, Govindan explains that there is a good strategy in place for at least half of the patients who progress beyond the first-generation EGFR inhibitor. In the coming years, investigators will find a way to combine various agents and, hopefully, come up with novel agents that move downstream to work alongside EGFR inhibitors, as well. 
 


Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Clinical practice is already changing, Govindan says, as physicians are biopsying patients at the time of disease progression and obtaining cell-free DNA analyses. Moreover, second-line therapy is being decided based on gene alterations.

Secondly, Govindan explains that there is a good strategy in place for at least half of the patients who progress beyond the first-generation EGFR inhibitor. In the coming years, investigators will find a way to combine various agents and, hopefully, come up with novel agents that move downstream to work alongside EGFR inhibitors, as well. 
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x